Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study

References

• GrunbergSMOsobaDHeskethPJEvaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an updateSupport Care Cancer2005132808415599601
   PubMed Web of Science ®Google Scholar
• Bloechl-DaumBDeusonRRMavrosPHansenMHerrstedtJDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol200624274472447816983116
   PubMed Web of Science ®Google Scholar
• HayashiTShimokawaMMiyoshiTA prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomitingSupport Care Cancer20172592707271428341971
   PubMed Web of Science ®Google Scholar
• du BoisAMeerpohlHGVachWKommossFGFenzlEPfleidererACourse, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetronEur J Cancer1992282–34504571534250
   PubMed Web of Science ®Google Scholar
• HeskethPNavariRGroteTDouble-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention GroupJ Clin Oncol1996148224222498708713
   PubMed Web of Science ®Google Scholar
• OsobaDZeeBPaterJWarrDLatreilleJKaizerLDeterminants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol19971511161238996132
   PubMed Web of Science ®Google Scholar
• PaterJSlametLZeeBOsobaDWarrDRusthovenJInconsistency of prognostic factors for post-chemotherapy nausea and vomitingSupport Care Cancer1994231611668032701
   PubMed Web of Science ®Google Scholar
• PolleraCFGiannarelliDPrognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic modelCancer1989645111711222667749
   PubMed Web of Science ®Google Scholar
• Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapyItalian Group for Antiemetic ResearchJ Clin Oncol1995139241724267666102
   PubMedGoogle Scholar
• RoilaFBoschettiETonatoMPredictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind studyAm J Clin Oncol19911432382422031511
   PubMed Web of Science ®Google Scholar
• RoilaFTonatoMBasurtoCAntiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical ResearchJ Clin Oncol1987511411493543234
   PubMed Web of Science ®Google Scholar
• TamuraKAibaKSaekiCINV Study Group of JapanTesting the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of JapanInt J Clin Oncol201520585586525681876
   PubMed Web of Science ®Google Scholar
• OlverIRuhlmannCHJahnF2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potentialSupport Care Cancer201725129730127572335
   PubMed Web of Science ®Google Scholar
• HeskethPJKrisMGBaschEAntiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJ Clin Oncol201735283240326128759346
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical Practice Guidelines in Oncology (2017) Antiemetics. Version 22017 Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdfAccessed April 30, 2018
   Google Scholar
• Japan Society of Clinical OncologyGuidelines for Antiemetics in Oncology 2015TokyoKanehara & Co, Ltd2015 Available from: https://www.kanehara-shuppan.co.jp/books/detail.html?isbn=9784307101745Accessed September 26, 2018 Japanese
   Google Scholar
• PirriCKatrisPTrotterJBaylissEBennettRDrummondPRisk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational studySupport Care Cancer201119101549156320811914
   PubMed Web of Science ®Google Scholar
• MolassiotisAAaproMDicatoMEvaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational studyJ Pain Symptom Manage2014475839848.e424075401
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJAprepitant Protocol 052 Study GroupThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study GroupJ Clin Oncol200321224112411914559886
   PubMed Web of Science ®Google Scholar
• NavariRMQinRRuddyKJOlanzapine for the prevention of chemotherapy-induced nausea and vomitingN Engl J Med2016375213414227410922
   PubMed Web of Science ®Google Scholar
• MolassiotisAFarrellCBourneKBrearleySGPillingMAn exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modelingJ Pain Symptom Manage201244569270322672920
   PubMed Web of Science ®Google Scholar
• OlverINEliottJAKoczwaraBA qualitative study investigating chemotherapy-induced nausea as a symptom clusterSupport Care Cancer201422102749275624805911
   PubMed Web of Science ®Google Scholar
• ItoYTsudaTMinatogawaHPlacebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapyJ Clin Oncol201836101000100629443652
   PubMed Web of Science ®Google Scholar
• VardyJChiewKSGalicaJPondGRTannockIFSide effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapyBr J Cancer20069471011101516552437
   PubMed Web of Science ®Google Scholar
• NakamuraMIshiguroAMuranakaTA prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01)Oncologist201722559260028341762
   PubMed Web of Science ®Google Scholar
• KomatsuYOkitaKYukiSOpen-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with PalonosetronCancer Sci2015106789189525872578
   PubMed Web of Science ®Google Scholar
• HeskethPJMorrowGKomorowskiAWAhmedRCoxDEfficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)Support Care Cancer201220102633263722733373
   PubMed Web of Science ®Google Scholar
• TamuraKAibaKSaekiTCINV Study Group of JapanBreakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of JapanInt J Clin Oncol201722240541227909835
   PubMed Web of Science ®Google Scholar
• NavariRMNagyCKGraySEThe use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapySupport Care Cancer20132161655166323314603
   PubMed Web of Science ®Google Scholar
• MussoMScaloneRBonannoVPalonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapySupport Care Cancer200917220520918839220
   PubMed Web of Science ®Google Scholar